Qubigen Secures Strategic Pre-Seed Investment from SYNthesis BioVentures to Advance Federated AI Drug Design
- David Brooks
- Dec 5, 2024
- 2 min read
Updated: Jun 5
Qubigen Pty Ltd is proud to announce that it has secured its first tranche of pre-seed equity funding from SYNthesis BioVentures through a SAFE note agreement. This initial investment marks a pivotal moment in Qubigen’s mission to revolutionise drug design through the application of federated AI and quantum chemistry.
The first tranche of funding will be directed toward applying Qubigen’s proprietary Federated AI platform to distributed drug development datasets and further integrating its state-of-the-art drug design algorithms. This work is designed to demonstrate the platform’s capacity to generate valid drug candidates; including molecules that are equal to or better than those currently being developed by pharmaceutical partners.
This financing milestone follows the merger of two leaders in the field: Qubist Molecular Design, recognised for its breakthroughs in AI-driven quantum chemistry and virtual screening, and Presagen, a pioneer in federated AI for healthcare. Together, they form Qubigen at the cutting edge of federated, AI-powered drug design.
Unlocking the second tranche of investment will be contingent on Qubigen achieving critical performance milestones, specifically the successful utilisation of external datasets to improve its algorithms and deliver high-potential drug candidates. Should these milestones be met, the second round of capital will provide runway to expand commercial partnerships and prepare for a Series A financing round.
SYNthesis BioVentures is the sole investor in this pre-seed round and brings not only capital but strategic alignment. Qubigen will be able to draw upon the deep expertise of SYNthesis Research in drug development, clinical trials, regulatory strategy, and biotech commercialisation. It will also benefit from organic synergies with other portfolio companies within SYNthesis BioVentures’ ecosystem.
Looking ahead, both parties anticipate a significant uplift in valuation, with follow-on financing expected to be secured by late Q3 of calendar year 2025, pending the successful achievement of technical milestones.
This investment sets the stage for Qubigen to accelerate its impact on the drug discovery landscape, helping partners transition from virtual drug candidates to real-world therapies, faster and more cost-effectively than ever before.
Qubigen - accelerate drug design without exposing secrets.
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next discovery.
